Comments
Alkem Laboratories on Friday informed the exchanges that it has received a letter from the US Food and Drug Administration directing it to withhold the manufacturing of products till completion of final evaluation. Earlier, the USFDA had issued Form 483 with eight observations during a pre-approval inspection for a product at the company’s manufacturing facility located at St Louis, US. The final decision by the USFDA would be communicated to the company accordingly, it said. Shares of Alkem Laboratories closed 1.24 per cent lower at ₹1,730.45 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.